Biofrontera AG logo

Biofrontera AG (0DOL)

Market Open
11 Aug, 15:30
2. 43
-0.22
-8.3019%
- Market Cap
- P/E Ratio
- Div Yield
2 Volume
0 Eps
2.65
Previous Close
Add Transaction
Day Range
2.43 2.53
Year Range
2.24 2.71
Want to track 0DOL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

0DOL trading today lower at €2.43, a decrease of -8.3019% from yesterday's close, completing a monthly increase of 8.4821% or €0.19. Over the past 12 months, 0DOL stock lost -4.3307%.
0DOL is not paying dividends to its shareholders.
The last earnings report, released on Jun 03, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Biofrontera AG has completed 5 stock splits, with the recent split occurring on Feb 08, 2021.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on CBOE (EUR).

0DOL Chart

Biofrontera AG (0DOL) FAQ

What is the stock price today?

The current price is €2.43.

On which exchange is it traded?

Biofrontera AG is listed on LSE.

What is its stock symbol?

The ticker symbol is 0DOL.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Biofrontera AG ever had a stock split?

Biofrontera AG had 5 splits and the recent split was on Feb 08, 2021.

Biofrontera AG Profile

Specialty Retail Industry
Consumer Discretionary Sector
Pilar de la Huerta Martinez CEO
LSE Exchange
DE000A4BGGM7 ISIN
DE Country
97 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Biofrontera AG is a biopharmaceutical company that is focused on the research, development, and commercialization of dermatological products. Established in 1997, the company has carved out a niche in the dermatology sector by bringing innovative solutions to the market, particularly for the treatment of skin conditions such as actinic keratoses, field cancerization, and squamous cell carcinoma. Biofrontera AG has established a strategic collaboration and partnership with Maruho Co., Ltd., enhancing its reach and development capabilities. Headquartered in Leverkusen, Germany, the company continues to focus on addressing unmet medical needs in dermatology.

Products and Services

  • Ameluz
  • Ameluz is a treatment developed by Biofrontera AG for mild and moderate actinic keratoses on the face and scalp. Actinic keratoses are rough, scaly patches on the skin, caused by years of sun exposure, which can potentially lead to skin cancer if left untreated. Ameluz is used in photodynamic therapy (PDT), a process that involves applying the medication to the lesions and then exposing them to a light source, leading to the destruction of the affected cells.

  • BF-RhodoLED Lamp
  • The BF-RhodoLED lamp is specifically designed to work in conjunction with Ameluz for the effective treatment of actinic keratoses through photodynamic therapy (PDT). This state-of-the-art lamp emits light at a precise wavelength, activating the applied drug and facilitating the targeted destruction of precancerous cells without harming the surrounding healthy skin.

  • RhodoLED XL
  • RhodoLED XL represents an advancement in the treatment of actinic keratoses, particularly designed for patients with multiple interspersed lesions. This larger version of the BF-RhodoLED lamp allows for the treatment of broader areas, making the PDT process more efficient and convenient for patients with extensive skin damage due to sun exposure.

  • Belixos
  • Belixos is a part of Biofrontera AG’s medical skin care range, specifically formulated for irritated and sensitive skin. This product line leverages the power of natural ingredients and scientific research to provide soothing relief and effective care for a variety of skin problems. Belixos products aim to calm, repair, and protect the skin, offering a gentle yet effective option for daily skincare.

Contact Information

Address: Hemmelrather Weg 201
Phone: 49 214 87 63 2 0